Placebo News and Research

RSS

Hemianopia patients confirm prism benefits

Results from a crossover trial confirm anecdotal reports that patients with homonymous hemianopia benefit from wearing peripheral prism glasses.

13 Nov 2013

Synergy Pharmaceuticals starts first phase 3 clinical trial of plecanatide in CIC patients

Synergy Pharmaceuticals Inc. today announced the start of the first of two planned phase 3 clinical trials to confirm the safety and efficacy of plecanatide, its lead GC-C agonist and once-daily oral treatment, in adult patients with chronic idiopathic constipation.

13 Nov 2013

FibroGen presents China-based Phase 2 study data of roxadustat for treatment of CKD patients

FibroGen, Inc. (FibroGen), today announced that data from a China-based Phase 2 study of roxadustat (FG-4592), a first-in-class oral compound in late stage development for the treatment of anemia associated with chronic kidney disease (CKD) and end-stage renal disease (ESRD), were presented in an oral session at the 2013 American Society of Nephrology (ASN) Kidney Week in Atlanta, Georgia.

13 Nov 2013

Neuroptis Biotech reports positive results from ML7 preclinical trials for eye surface diseases

Neuroptis Biotech, the ophthalmology drug research and development specialist, announces positive results in preclinical trials of the eye-drop formulation of its ML7 product. ML7 is intended for use in the treatment of eye surface diseases, particularly dry eye.

13 Nov 2013

XTANDI now accepted for use within NHS Scotland for treatment of adult men with mCRPC

The Scottish Medicines Consortium, which advises NHS Scotland on prescribing new treatments, announced today that XTANDI (enzalutamide) is accepted for unrestricted use within NHS Scotland for the treatment of adult men with metastatic castration-resistant prostate cancer whose disease has progressed on or after docetaxel therapy.

13 Nov 2013

Orexigen Therapeutics reports net loss of $18.6 million in Q3 2013

Orexigen Therapeutics, Inc., a biopharmaceutical company focused on the treatment of obesity, today announced business and financial results for the third quarter ended September 30, 2013.

12 Nov 2013

Shield Therapeutics files IND application with FDA to initiate ST10 Phase 3 study

Shield Therapeutics, an independent specialty pharmaceutical company focused on the development of mineral-derived hospital pharmaceuticals, today announces that it has filed an investigational new drug application with the US Food and Drug Administration to initiate a Phase 3 pivotal study of ST10, its novel oral iron-replacement therapy, for the treatment of iron deficiency anaemia in pre-dialysis patients with chronic kidney disease.

12 Nov 2013

Peripheral prism glasses provide simple mobility rehabilitation intervention for hemianopia

More than a million Americans suffer from hemianopia, or blindness in one half of the visual field in both eyes as the result of strokes, tumors or trauma. People with hemianopia frequently bump into walls, trip over objects, or walk into people on the side where the visual field is missing.

12 Nov 2013

Zalicus announces top-line results from Z160 Phase 2 clinical studies in chronic pain indications

Zalicus Inc., a biopharmaceutical company that discovers and develops novel treatments for patients suffering from pain, today announced top-line results from two Phase 2 clinical studies of Z160 in chronic pain indications.

11 Nov 2013

GW Pharmaceuticals starts Phase 1b/2a clinical trial for Recurrent Glioblastoma Multiforme

GW Pharmaceuticals plc a biopharmaceutical company focused on discovering, developing and commercializing novel therapeutics from its proprietary cannabinoid product platform, announced today it has commenced a Phase 1b/2a clinical trial for the treatment of Recurrent Glioblastoma Multiforme.

11 Nov 2013

Researchers launch clinical trial of investigational vaccine designed to prevent genital herpes disease

Researchers have launched an early-stage clinical trial of an investigational vaccine designed to prevent genital herpes disease. The National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health, is sponsoring the Phase I trial, which is being conducted at the NIH Clinical Center in Bethesda, Md.

11 Nov 2013

Aptiom receives FDA approval to treat seizures associated with epilepsy

The U.S. Food and Drug Administration today approved Aptiom (eslicarbazepine acetate) as an add-on medication to treat seizures associated with epilepsy.

10 Nov 2013

BioCryst Pharmaceuticals initiates BCX4161 Phase 2a trial in HAE patients

BioCryst Pharmaceuticals, Inc. today announced that it has dosed the first subject in OPuS-1 (Oral ProphylaxiS-1), a Phase 2a proof of concept clinical trial of orally-administered BCX4161 in patients with hereditary angioedema.

8 Nov 2013

Brain & Behavior Research Foundation announces recipients of NARSAD Investigator Grants

The Brain & Behavior Research Foundation (formerly known as NARSAD, the National Alliance for Research on Schizophrenia and Depression), under the direction of Dr. Jeffrey Borenstein, President & CEO, has announced the latest recipients of its NARSAD Distinguished Investigator Grants.

8 Nov 2013

$Risedronate may help prevent new vertebral fractures when taken with calcium and vitamin D$

Risedronate may help prevent new vertebral fractures when taken with calcium and vitamin D

A recent prospective, randomized, placebo-controlled clinical trial reports that calcium and vitamin D supplementation improves bone density in a group of male veterans with epilepsy who were treated chronically with antiepileptic drugs.

8 Nov 2013

Vitamin C can improve skeletal muscle fatigue in COPD patients

Chronic obstructive pulmonary disease—a health problem in which the lungs lose their inherent springiness, making it progressively harder to breathe—can have a dramatic effect on the ability to exercise and even perform simple activities of daily life because of the disease's fallout effects on skeletal muscles.

8 Nov 2013

Vitamin D and calcium improves bone density in male veterans treated with AEDs

8 Nov 2013

Study finds few beneficial effects of metformin drug for cardiovascular disease in people without diabetes

Despite high expectations for the commonly used diabetes drug metformin to improve risk factors for heart disease in people without diabetes, few beneficial effects have been found in a randomised trial of patients with established cardiovascular disease, published in The Lancet Diabetes & Endocrinology.

7 Nov 2013

Linagliptin shows efficacy, tolerability in adults with T2D and liver disease

Boehringer Ingelheim and Eli Lilly and Company announce new data that reinforce the efficacy and tolerability of linagliptin in people with Type 2 Diabetes and liver disease, as well as Asian people with T2D aged 65 years or older.

7 Nov 2013

Natura Therapeutics’ natural dietary intervention improves older adults' cognitive functioning

A human clinical study of older adults has demonstrated that participants who took NutraStem Cardio-, a natural dietary supplement created by Natura Therapeutics, Inc., showed a significant increase in cognition when compared to age-matched individuals taking a placebo.

7 Nov 2013

Placebo News and Research

Hemianopia patients confirm prism benefits

Synergy Pharmaceuticals starts first phase 3 clinical trial of plecanatide in CIC patients

FibroGen presents China-based Phase 2 study data of roxadustat for treatment of CKD patients

Neuroptis Biotech reports positive results from ML7 preclinical trials for eye surface diseases

XTANDI now accepted for use within NHS Scotland for treatment of adult men with mCRPC

Orexigen Therapeutics reports net loss of $18.6 million in Q3 2013

Shield Therapeutics files IND application with FDA to initiate ST10 Phase 3 study

Peripheral prism glasses provide simple mobility rehabilitation intervention for hemianopia

Zalicus announces top-line results from Z160 Phase 2 clinical studies in chronic pain indications

GW Pharmaceuticals starts Phase 1b/2a clinical trial for Recurrent Glioblastoma Multiforme

Researchers launch clinical trial of investigational vaccine designed to prevent genital herpes disease

Aptiom receives FDA approval to treat seizures associated with epilepsy

BioCryst Pharmaceuticals initiates BCX4161 Phase 2a trial in HAE patients

Brain & Behavior Research Foundation announces recipients of NARSAD Investigator Grants

Risedronate may help prevent new vertebral fractures when taken with calcium and vitamin D

Vitamin C can improve skeletal muscle fatigue in COPD patients

Vitamin D and calcium improves bone density in male veterans treated with AEDs

Study finds few beneficial effects of metformin drug for cardiovascular disease in people without diabetes

Linagliptin shows efficacy, tolerability in adults with T2D and liver disease

Natura Therapeutics’ natural dietary intervention improves older adults' cognitive functioning

Advancing Neuroscience Research Through Collaboration and Patient-Centered Innovation

The impact of vibration on microscopy

How Omics Technologies Are Transforming Biological Research and Drug Discovery

Latest News